Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PVLA Palvella Therapeutics

盘后交易 04-14 18:18:15 EDT

129.53

+0.53

+0.41%

盘后129.53

+0.000.00%

16:10 EDT

最高132.53	最低127.20	成交量12.17万
今开129.19	昨收129.00	日振幅4.13%
总市值18.54亿	流通市值10.88亿	总股本1,431万
成交额1,570万	换手率1.45%	流通股本839.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":129.53,"timestamp":1776196800000,"preClose":129,"halted":0,"volume":121655,"hourTrading":{"tag":"盘后","latestPrice":129.53,"preClose":129.53,"latestTime":"16:10 EDT","volume":2011,"amount":260484.83000000002,"timestamp":1776197405342,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004108527131782954,"floatShares":8398100,"shares":14313699,"eps":-3.707588,"marketStatus":"盘后交易","change":0.53,"latestTime":"04-14 18:18:15 EDT","open":129.19,"high":132.525,"low":127.2,"amount":15704955.58761,"amplitude":0.041279,"askPrice":132.17,"askSize":9,"bidPrice":123.3,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.707588,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776211200000},"marketStatusCode":4,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":129,"preHourTrading":{"tag":"盘前","latestPrice":129,"preClose":129,"latestTime":"08:10 EDT","volume":90,"amount":11613.5406,"timestamp":1776168631009,"change":0,"changeRate":0,"amplitude":0.00124},"postHourTrading":{"tag":"盘后","latestPrice":129.53,"preClose":129.53,"latestTime":"16:10 EDT","volume":2011,"amount":260484.83000000002,"timestamp":1776197405342,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.514974,"impliedVol":0.6441,"impliedVolPercentile":0.324},"requestUrl":"/m/hq/s/PVLA/tweets","defaultTab":"tweets","newsList":[{"id":"1101160402","title":"Palvella Therapeutics任命罕见皮肤病领域权威皮肤科医生John D. Doux博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1101160402","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101160402?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:34","pubTimestamp":1776080044,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics近日宣布，正式任命约翰·D·杜克斯医学博士、工商管理硕士加入其董事会。杜克斯博士是皮肤医学领域的资深专家，尤其在罕见皮肤疾病的研究与临床治疗方面享有盛誉。此次人事变动将为公司带来宝贵的专业见解和行业领导力，进一步强化其在罕见皮肤病治疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139195793","title":"异动解读 | Palvella Therapeutics新药申请进展顺利，盘中大涨9.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139195793","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139195793?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:40","pubTimestamp":1774964431,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA)今日盘中大涨9.42%，引起了市场的广泛关注。消息面上，生物制药公司Palvella Therapeutics宣布，其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进，预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步，增强了投资者对公司研发管线进展和未来商业化前景的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162347775","title":"Palvella公司Qtorin Rapamycin治疗微囊性淋巴管畸形的新药申请按计划将于2026年下半年提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1162347775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162347775?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:33","pubTimestamp":1774956825,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics宣布，其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进，预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111986483","title":"Palvella Therapeutics将于2026年3月31日召开2025财年全年业绩电话会议并公布公司最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1111986483","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111986483?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:30","pubTimestamp":1774351813,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，计划于2026年3月31日举行2025财年全年财务业绩电话会议。此次会议将详细披露公司全年财务表现，并就业务运营、研发管线及战略规划提供最新动态。\n投资者及公众可通过指定渠道接入会议，与管理层直接交流，深入了解公司发展近况与未来展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129093196","title":"Palvella Therapeutics任命罕见病商业领袖Jennifer J. Mcdonough为市场准入与患者服务高级副总裁，强化领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1129093196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129093196?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:35","pubTimestamp":1774265729,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布了一项重要人事任命，罕见病领域的商业领袖Jennifer J. Mcdonough已加入公司，担任市场准入与患者服务高级副总裁。这一举措旨在加强公司的领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156228122","title":"Palvella Therapeutics携手顶尖非营利组织 启动针对微囊型淋巴管畸形的“Beyond MLM”疾病认知行动","url":"https://stock-news.laohu8.com/highlight/detail?id=1156228122","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156228122?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:30","pubTimestamp":1773142217,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics（简称PVLA）宣布，已联合多家领先的淋巴、血管及皮肤病学领域非营利组织，共同启动了名为“Beyond MLM”的疾病认知推广活动。该倡议旨在提升公众对微囊型淋巴管畸形这一疾病的认识与理解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185545003","title":"Palvella Therapeutics股价盘前飙升23%，其皮肤病药物达成后期试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1185545003","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185545003?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:55","pubTimestamp":1771937734,"startTime":"0","endTime":"0","summary":"在宣布其针对罕见皮肤病的研究药物成功达成一项关键后期试验的主要目标后，Palvella Therapeutics的股价在盘前交易中大幅上涨了23%。这一积极结果极大地提振了投资者信心，预示着该疗法在寻求监管批准的道路上迈出了关键一步。该公司的前景因此次试验成功而显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198934231","title":"Palvella Therapeutics在预设关键次要终点及全部四项次要疗效终点均达到统计学显著性（所有P值均小于0.001）","url":"https://stock-news.laohu8.com/highlight/detail?id=1198934231","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198934231?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:33","pubTimestamp":1771932795,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics宣布，其临床研究在预设的关键次要终点上取得了统计学显著性结果，P值小于0.001。此外，该研究还成功在所有四项次要疗效终点上均显示出统计学显著性，所有P值同样低于0.001。\n这一系列积极数据进一步验证了该公司在研疗法的有效性与可靠性，为后续研发及监管申报提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169232983","title":"Palvella Therapeutics公布Qtorin™ 3.9%雷帕霉素无水凝胶治疗微囊型淋巴管畸形三期Selva临床研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1169232983","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169232983?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:32","pubTimestamp":1771932736,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公司宣布，其针对微囊型淋巴管畸形（Microcystic Lymphatic Malformations）的候选药物Qtorin™ 3.9%雷帕霉素无水凝胶（Qtorin™ Rapamycin），在三期Selva临床研究中取得了积极的顶线结果。\n该研究成功达到了其主要疗效终点，显示出具有高度统计学显著性和临床意义的改善。安全性数据与药物已知的安全性特征一致，未发现新的安全信号。\n这一积极数据是推动该疗法向监管提交申请的关键一步，为患有这种罕见疾病的患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161160003","title":"Palvella Therapeutics计划于2026年下半年向FDA提交新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1161160003","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161160003?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:31","pubTimestamp":1771932675,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics Inc (PVLA) 近日公布了其关键药物的最新进展。根据公司规划，Palvella预计将在2026年下半年向美国食品药品监督管理局（FDA）正式提交新药申请（NDA）。这一时间表的公布，标志着该公司核心研发项目进入了重要的冲刺阶段，为后续的商业化进程奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144468815","title":"Palvella Therapeutics将召开电话会议 讨论Qtorin™雷帕霉素无水凝胶治疗微囊型淋巴管畸形三期临床试验关键结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1144468815","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144468815?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:00","pubTimestamp":1771884016,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布将举办专题电话会议，重点解读其候选药物Qtorin™ 3.9%雷帕霉素无水凝胶（Qtorin™ Rapamycin）针对微囊型淋巴管畸形适应症的三期Selva临床试验的顶线结果。此次会议将深入探讨该试验的核心数据及其潜在临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612255671","title":"Palvella Therapeutics, Inc.盘中异动 下午盘急速拉升5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612255671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612255671?lang=zh_cn&edition=full","pubTime":"2026-02-20 03:23","pubTimestamp":1771529003,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日03时23分，Palvella Therapeutics, Inc.股票出现异动，股价急速上涨5.35%。Palvella Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Palvella Therapeutics, Inc.公司简介：Palvella Therapeutics Inc 是一家晚期临床阶段的生物制药公司，致力于为那些患有严重的、罕见的遗传皮肤病的患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022003232495417a00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022003232495417a00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PVLA","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134522020","title":"Palvella Therapeutics发布公司进展与2026年展望：推进后期临床阶段管线，以平台化策略攻克无FDA批准疗法的严重罕见皮肤病及血管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1134522020","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134522020?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:30","pubTimestamp":1767961814,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics近期披露了公司最新动态及面向2026年的战略规划。该公司正全力推进其处于后期临床阶段的产品管线与技术平台，致力于解决目前尚无美国食品药品监督管理局（FDA）批准疗法的多种严重罕见皮肤病及血管畸形疾病。这一举措凸显了公司聚焦未满足临床需求的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132581978","title":"Palvella Therapeutics 获得 FDA 快速通道认证，用于治疗血管角化瘤的 Qtorin™ 3.9% 干燥雷帕霉素凝胶 (Qtorin™ Rapamycin)","url":"https://stock-news.laohu8.com/highlight/detail?id=1132581978","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132581978?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:30","pubTimestamp":1765888255,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 获得 FDA 快速通道认证，用于治疗血管角化瘤的 Qtorin™ 3.9% 干燥雷帕霉素凝胶 (Qtorin™ Rapamycin)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123205248","title":"Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶（Qtorin™ Rapamycin）治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123205248","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123205248?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:01","pubTimestamp":1765796473,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶（Qtorin™ Rapamycin）治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果。这是一种严重的罕见遗传疾病，目前尚无FDA批准的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134453895","title":"Palvella Therapeutics股价上涨11.2%，因Raymond James将评级从“跑赢大盘”上调至“强烈买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=1134453895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134453895?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:28","pubTimestamp":1763573311,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics股价上涨11.2%，因Raymond James将评级从“跑赢大盘”上调至“强烈买入”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121184983","title":"Palvella Therapeutics发布2025年第三季度财务业绩并提供公司更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1121184983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121184983?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:24","pubTimestamp":1763573099,"startTime":"0","endTime":"0","summary":"11月11日 - Palvella Therapeutics Inc 发表声明：*PALVELLA THERAPEUTICS发布2025年第三季度财务业绩并提供公司更新*PALVELLA THERAPEUTICS INC：第三季度每股收益为-$1.03","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156492120","title":"Palvella Therapeutics：Raymond James将评级上调至强力买入，目标价格由92美元提高至143美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156492120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156492120?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:12","pubTimestamp":1763554332,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics：Raymond James将评级上调至强力买入，目标价格由92美元提高至143美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160931524","title":"Palvella Therapeutics 宣布推出 Qtorin™ 新产品候选者 Qtorin™ Pitavastatin，用于治疗一种罕见的慢性前癌性遗传皮肤疾病——扩散性浅表性光敏性角化病（Dsap），该疾病尚无 FDA 批准的治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1160931524","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160931524?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:01","pubTimestamp":1762340484,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 宣布推出 Qtorin™ 新产品候选者 Qtorin™ Pitavastatin，用于治疗一种罕见的慢性前癌性遗传皮肤疾病——扩散性浅表性光敏性角化病（Dsap），该疾病尚无 FDA 批准的治疗方案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509407655","title":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407655","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509407655?lang=zh_cn&edition=full","pubTime":"2025-02-05 20:11","pubTimestamp":1738757515,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05201147968471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TD","PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":0.0763},{"period":"1month","weight":0.0569},{"period":"3month","weight":0.2459},{"period":"6month","weight":0.6905},{"period":"1year","weight":4.9283},{"period":"ytd","weight":0.2324}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Palvella Therapeutics, Inc.在内华达的法律下成立于2013年5月24日。该公司是一家生物技术公司，历史上发现并开发了基于Anticalin蛋白的药物，以独特和变革性的方式靶向已验证的疾病途径。2024年3月27日，公司实施了措施，以最大限度地提高其从其合作候选药物临床管道收集潜在里程碑的能力，并保持其考虑其他战略选择的能力。该公司的临床管线包括与合作者合作的免疫肿瘤学或IO双特异性药物，包括靶向PD-L1和4-1BB的S095012（也称PRS-344）、靶向CD228和4-1BB的SGN-BB228（也称PRS-346）以及靶向GPC3和4-1BB的BOS-342（也称PRS-342）。Anticalin蛋白是公司专有的，是一类新型疗法，已在临床上通过与领先制药公司的合作关系得到验证。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.069248},{"month":2,"riseRate":0.545455,"avgChangeRate":0.088954},{"month":3,"riseRate":0.454545,"avgChangeRate":0.004194},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.071479},{"month":5,"riseRate":0.5,"avgChangeRate":0.168212},{"month":6,"riseRate":0.4,"avgChangeRate":-0.088952},{"month":7,"riseRate":0.727273,"avgChangeRate":0.169693},{"month":8,"riseRate":0.636364,"avgChangeRate":0.117993},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.090465},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.051298}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}